Oracle Announces Release of Remote Data Capture 4.6
Oracle (Redwood Shores, CA) announced the release of Remote Data Capture 4.6. The company collaborated with customer advisors to develop additional functions for the EDC application. The latest additions include scalability improvements, flexible branching to support complex trial design (including for oncology trials), access restriction capabilities, and patient management enhancements.
Remote Data Capture is integrated with the company’s clinical data management system, Oracle Clinical.
“R&D efficiency, clinical effectiveness and time to market continue to be the greatest challenges facing life sciences organizations today,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences, in a company press release. “Oracle Remote Data Capture 4.6 provides strong evidence of our unwavering commitment to helping clinical trial sponsors and CROs accelerate insights for better health, and will enable our customers to complete clinical trials significantly faster and much more cost effectively than ever before.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
